AP
IRWD icon

AHL Partners’s Ironwood Pharmaceuticals IRWD Stock Holding History

AHL Partners’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$291K Buy
+23,204
New +$303K ﹤0.01% 1170

Other funds holding IRWD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AHL Partners's IRWD Position: Q4 2017 in Review

AHL Partners opened a new position in Ironwood Pharmaceuticals (IRWD) in Q4 2017: 23,204 shares worth $291K. The stake represents ﹤0.01% of the portfolio and ranks #1170 among its holdings.

158 funds tracked by Wall St. Rank hold IRWD as of Q4 2017.

  • AHL Partners held 23,204 shares of Ironwood Pharmaceuticals worth $291K as of Q4 2017.
  • Ironwood Pharmaceuticals was a new AHL Partners position in Q4 2017.
  • Ironwood Pharmaceuticals made up ﹤0.01% of AHL Partners's portfolio in Q4 2017, its #1170 holding.
  • 158 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.